Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2005 May;62(9):1025-37.
doi: 10.1007/s00018-005-4528-2.

Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding

S Tenzer  1 , B Peters, S Bulik, O Schoor, C Lemmel, M M Schatz, P-M Kloetzel, H-G Rammensee, H Schild, H-G Holzhütter
Affiliations
Comparative Study

Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding

S Tenzer et al. Cell Mol Life Sci. 2005 May.

Abstract

Epitopes presented by major histocompatibility complex (MHC) class I molecules are selected by a multi-step process. Here we present the first computational prediction of this process based on in vitro experiments characterizing proteasomal cleavage, transport by the transporter associated with antigen processing (TAP) and MHC class I binding. Our novel prediction method for proteasomal cleavages outperforms existing methods when tested on in vitro cleavage data. The analysis of our predictions for a new dataset consisting of 390 endogenously processed MHC class I ligands from cells with known proteasome composition shows that the immunological advantage of switching from constitutive to immunoproteasomes is mainly to suppress the creation of peptides in the cytosol that TAP cannot transport. Furthermore, we show that proteasomes are unlikely to generate MHC class I ligands with a C-terminal lysine residue, suggesting processing of these ligands by a different protease that may be tripeptidyl-peptidase II (TPPII).

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. JACC Heart Fail. 2015 Nov;3(11):873-82 - PubMed
    1. N Engl J Med. 1999 Aug 26;341(9):625-34 - PubMed
    1. Eur Heart J Acute Cardiovasc Care. 2016 Nov;5(7):13-22 - PubMed
    1. Am J Med. 2015 Jun;128(6):601-8 - PubMed
    1. J Am Coll Cardiol. 2015 Dec 15;66(23):2663-74 - PubMed

Publication types

MeSH terms

LinkOut - more resources

-